Q3 2020 Alligator Bioscience AB Earnings Call Transcript
© -
Thank you so much. So welcome to this conference call, which will focus on today's interim report and the associated press release.
Slide 2. So as usual, the presentation does include some forward-looking statements.
Let's go to slide 3. We announced today that Alligator will focus clinical activities to our lead programs ATOR-1017 and mitazalimab. In short, the decision is based on the strong positioning and positive data for these two programs. One, there is a need for further evaluation of data in the ATOR-1015 program. So, our focus will be on ATOR-1017 and [mitam], while further clinical development for ATOR-1015 is to be conducted with a partner. These are the key messages, and I will now go into this in more detail.
First a slide summarizing the most recent news flow, Slide 4. So, during this third quarter, we had presented data from all three clinical programs as well as a novel bispecific drug concept, Neo-X-Prime and the recruitment of Gayle Mills as Chief Business Officer at Alligator.
Let's now
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |